Medtronic, Inc. MDT today announced U.S.
Food and Drug Administration (FDA) 510(k) clearance and the first U.S.
clinical uses of its new Affinity Fusion^® oxygenation system. This system,
which is designed to serve as a patient's lungs by oxygenating and removing
carbon dioxide from blood during various open-heart surgical procedures,
incorporates numerous innovations for patient safety and ease of use. Notably,
system enhancements are designed to prevent and remove air bubbles that can
enter the blood during the procedure, which may potentially reduce the risk of
stroke.
The Affinity Fusion oxygenation system's new design enhancements include:
o A proprietary fiber winding process with an interlaced pattern that
efficiently filters the blood and removes particles and air while at the
same time oxygenating the blood;
o Smooth tubular pathways for blood to pass through and a first-of-its-kind
curved venous inlet tube, both of which can reduce blood turbulence during
the surgical procedure;
o Enhanced setup and customization capabilities, including a new oxygenator
system holder, which gives perfusionists improved flexibility and ease of
use in various operating rooms, including those with limited space.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in